Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enlivex Therapeutics Ltd (NQ: ENLV ) 1.261 +0.023 (+1.88%) Streaming Delayed Price Updated: 3:40 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 27,022 Open 1.296 Bid (Size) 1.270 (10) Ask (Size) 1.290 (2) Prev. Close 1.238 Today's Range 1.220 - 1.296 52wk Range 1.150 - 4.590 Shares Outstanding 18,306,186 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis July 23, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV July 19, 2024 Via ACCESSWIRE Performance YTD -61.79% -61.79% 1 Month -6.95% -6.95% 3 Month -11.21% -11.21% 6 Month -61.44% -61.44% 1 Year -50.17% -50.17% More News Read More CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV) July 17, 2024 Via AB Newswire Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis June 24, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 June 20, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis June 17, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis June 03, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering May 29, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering May 28, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session April 29, 2024 Via Benzinga Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events April 29, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis April 22, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis April 16, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday April 12, 2024 Via Benzinga Nasdaq Jumps 250 Points; Crude Oil Down 1% April 11, 2024 Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis April 11, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session April 11, 2024 Via Benzinga Dow Dips 100 Points; CarMax Earnings Miss Views April 11, 2024 Via Benzinga Topics Earnings Stocks Exposures Financial US Equities Nasdaq Gains Over 50 Points; US Producer Prices Increase In March April 11, 2024 Via Benzinga Topics Stocks Exposures US Equities Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis April 11, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023 April 05, 2024 Via InvestorPlace Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV March 22, 2024 Via ACCESSWIRE Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis February 26, 2024 Via ACCESSWIRE Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals February 21, 2024 Via ACCESSWIRE Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method February 07, 2024 From Enlivex Therapeutics Ltd Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
